Pharmacoeconomics Of Ruxolitinib Therapy In Patients With Myelofibrosis
| Autor: | João Almeida, Valeska Andreozzi, João Paulo Fernandes Felix, Björn Vandewalle |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Pediatrics
medicine.medical_specialty Ruxolitinib Blood transfusion Cost effectiveness Cost-Benefit Analysis medicine.medical_treatment Antineoplastic Agents 03 medical and health sciences Pharmacoeconomics 0302 clinical medicine Nitriles medicine Overall survival Humans In patient Economics Pharmaceutical Myelofibrosis Intensive care medicine Protein Kinase Inhibitors Randomized Controlled Trials as Topic business.industry Health Policy Public Health Environmental and Occupational Health Health Services medicine.disease Clinical trial Pyrimidines Primary Myelofibrosis 030220 oncology & carcinogenesis Quality of Life Life expectancy Pyrazoles business Models Econometric 030215 immunology medicine.drug |
| Zdroj: | Value in Health. 18(7) |
| ISSN: | 1098-3015 |
| DOI: | 10.1016/j.jval.2015.09.1168 |
| Popis: | Overall survival (OS) and other important clinical trial end-points seem increasingly more elusive in supporting rapid and efficient incorporation of innovative cancer drugs in clinical practice. This study proposes a clinical trial based pharmacoeconomic framework to assess the therapeutic and economic value of ruxolitinib in patients with intermediate-2 or high-risk myelofibrosis.Individual patient level 144 week follow-up data from the COMFORT-II trial was used to account for the crossover effect on overall survival. Lifetime treatment benefits and costs were estimated considering detailed patterns of both ruxolitinib dose adjustments and blood transfusion needs.The authors estimate a 3.3 years increment in life expectancy (HR = 0.30; 95% CI = 0.17-0.55; p-value0.001) and an incremental cost-effectiveness ratio of €40,000 per life year gained with the use of ruxolitinib.This study also demonstrates how valuable information from clinical trials can be used to support informed decisions about the early incorporation of innovative drugs. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect